Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer M Russo, G Siravegna, LS Blaszkowsky, G Corti, G Crisafulli, ... Cancer discovery 6 (2), 147-153, 2016 | 411 | 2016 |
Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer M Russo, S Misale, G Wei, G Siravegna, G Crisafulli, L Lazzari, G Corti, ... Cancer discovery 6 (1), 36-44, 2016 | 300* | 2016 |
Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer S Misale, S Arena, S Lamba, G Siravegna, A Lallo, S Hobor, M Russo, ... Science translational medicine 6 (224), 224ra26-224ra26, 2014 | 292 | 2014 |
Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer S Arena, B Bellosillo, G Siravegna, A Martínez, I Canadas, L Lazzari, ... Clinical cancer research 21 (9), 2157-2166, 2015 | 281 | 2015 |
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer F Pietrantonio, F Di Nicolantonio, AB Schrock, J Lee, S Tejpar, ... Journal of the National Cancer Institute 109 (12), 2017 | 234 | 2017 |
Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver A Bertocchi, S Carloni, PS Ravenda, G Bertalot, I Spadoni, AL Cascio, ... Cancer cell 39 (5), 708-724. e11, 2021 | 233 | 2021 |
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer BO Van Emburgh, S Arena, G Siravegna, L Lazzari, G Crisafulli, G Corti, ... Nature communications 7 (1), 13665, 2016 | 206 | 2016 |
Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis A Gentile, L Lazzari, S Benvenuti, L Trusolino, PM Comoglio Cancer research 71 (8), 3132-3141, 2011 | 165 | 2011 |
Radiologic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer G Siravegna, L Lazzari, G Crisafulli, A Sartore-Bianchi, B Mussolin, ... Cancer Cell 34 (1), 148-162. e7, 2018 | 139 | 2018 |
RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells S Lamba, M Russo, C Sun, L Lazzari, C Cancelliere, W Grernrum, ... Cell reports 8 (5), 1475-1483, 2014 | 129 | 2014 |
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations S Arena, G Siravegna, B Mussolin, JD Kearns, BB Wolf, S Misale, ... Science translational medicine 8 (324), 324ra14-324ra14, 2016 | 97 | 2016 |
Ron Kinase Transphosphorylation Sustains MET Oncogene Addiction S Benvenuti, L Lazzari, A Arnesano, G Li Chiavi, A Gentile, PM Comoglio Cancer research 71 (5), 1945-1955, 2011 | 83 | 2011 |
A subset of colorectal cancers with cross-sensitivity to olaparib and oxaliplatin S Arena, G Corti, E Durinikova, M Montone, NM Reilly, M Russo, ... Clinical Cancer Research 26 (6), 1372-1384, 2020 | 75 | 2020 |
Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients G Crisafulli, A Sartore-Bianchi, L Lazzari, F Pietrantonio, A Amatu, ... Cancer Discovery 12 (7), 1656-1675, 2022 | 60 | 2022 |
Patient-derived xenografts and matched cell lines identify pharmacogenomic vulnerabilities in colorectal cancer L Lazzari, G Corti, G Picco, C Isella, M Montone, P Arcella, E Durinikova, ... Clinical Cancer Research 25 (20), 6243-6259, 2019 | 56 | 2019 |
The ROR1 pseudokinase diversifies signaling outputs in MET‐addicted cancer cells A Gentile, L Lazzari, S Benvenuti, L Trusolino, PM Comoglio International journal of cancer 135 (10), 2305-2316, 2014 | 55 | 2014 |
Vitamin C restricts the emergence of acquired resistance to EGFR-targeted therapies in colorectal cancer A Lorenzato, A Magrì, V Matafora, V Audrito, P Arcella, L Lazzari, ... Cancers 12 (3), 685, 2020 | 48 | 2020 |
Met-driven invasive growth involves transcriptional regulation of Arhgap12 A Gentile, L D'alessandro, L Lazzari, B Martinoglio, A Bertotti, A Mira, ... Oncogene 27 (42), 5590-5598, 2008 | 41 | 2008 |
Amyloid aggregates accumulate in melanoma metastasis modulating YAP activity V Matafora, F Farris, U Restuccia, S Tamburri, G Martano, C Bernardelli, ... EMBO reports 21 (9), e50446, 2020 | 29 | 2020 |
The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients. S Lonardi, C Montagut, F Pietrantonio, E Elez, A Sartore-Bianchi, ... Journal of Clinical Oncology 38 (15_suppl), TPS4124-TPS4124, 2020 | 25 | 2020 |